Cargando…

P1489: MANAGEMENT OF SICKLE CELL DISEASE WITH HYDROXYUREA: A SYSTEMATIC REVIEW FROM LOW- AND MIDDLE-INCOME COUNTRIES

Detalles Bibliográficos
Autores principales:	Paintsil, V., Marfo, K., Adisa, F., Khan, S., Tshilolo, L. M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2022
Materias:	Posters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9429030/ http://dx.doi.org/10.1097/01.HS9.0000848812.59349.97

Ejemplares similares

P-007: HYDROXYUREA FOR THE MANAGEMENT OF SICKLE CELL DISEASE IN LOW- AND MIDDLE-INCOME COUNTRIES: A SYSTEMATIC REVIEW (2000–2022)
por: L., TSHILOLO, et al.
Publicado: (2022)

Evidence review of hydroxyurea for the prevention of sickle cell complications in low-income countries
por: Mulaku, Mercy, et al.
Publicado: (2013)

P-009: IDENTIFYING BARRIERS FOR PATIENTS WITH SICKLE CELL DISEASE TO ACCESS TREATMENT WITH HYDROXYUREA – A QUALITATIVE ANALYSIS OF THE SUPPLY CHAIN IN GHANA
por: S., GRAVEN, et al.
Publicado: (2022)

P1425: SYSTEMATIC INVESTIGATION OF HYDROXYUREA TREATMENT EFFECT IN PEDIATRIC PATIENTS WITH SICKLE CELL DISEASE
por: Bhat, Varsha, et al.
Publicado: (2023)

P138: WHITE PAPER: ASSESSMENT OF INTERNATIONAL SICKLE CELL DISEASE GUIDELINES IN HIGH-, MIDDLE-, AND LOW-INCOME COUNTRIES
por: Suthar, N, et al.
Publicado: (2022)

P-034: EFFECTS OF HYDROXYUREA ON SKELETAL MUSCLE MICROVASCULATURE OF MICE WITH SICKLE CELL DISEASE
por: M., RICCETTI, et al.
Publicado: (2022)

P-048: INFLUENCE OF SEVEN GENETIC POLYMORPHISMS ON THE RESPONSE TO SICKLE CELL DISEASE THERAPY WITH HYDROXYUREA
por: O., FRANCO SANTOS, et al.
Publicado: (2022)

P1446: HYDROXYUREA AND LIMB ULCERS: IS IT WORTH SUSPENDING? RETROSPECTIVE COHORT STUDY OF BRAZILIAN ADULT PATIENTS WITH SICKLE CELL DISEASE
por: Benites, Bruno, et al.
Publicado: (2023)

Access to cardiovascular medicines in low- and middle-income countries: a mini review
por: Harrison, Mark Amankwa, et al.
Publicado: (2023)

P-090: IS A DEDICATED MARKETING APPROVAL OF HYDROXYUREA IN SICKLE CELL DISEASE MAY INCREASE THE CLINICAL BENEFIT OF THE DRUG?
por: F., GALACTÉROS, et al.
Publicado: (2022)

Hydroxyurea Treatment for Sickle Cell Disease
por: Steinberg, Martin H.
Publicado: (2002)

P1418: DETERMINANTS OF HAEMOGLOBIN IN SICKLE CELL DISEASE PATIENTS IN SUB-SAHARAN AFRICA: MAJOR IMPACT OF THE NATIVE COUNTRY AND INDEPENDENT EFFECTS OF INFLAMMATION AND HAEMOLYSIS.
por: Rossi, Marica, et al.
Publicado: (2023)

Management of neonatal jaundice in low-income and middle-income countries
por: Erdeve, Omer
Publicado: (2020)

P102: PLASMA FREE HEMOGLOBIN AND REACTIVE OXYGEN SPECIES IN SICKLE CELL ANAEMIA PATIENTS UNDER HYDROXYUREA AND GLUTAMINE THERAPY
por: Giannaki, A, et al.
Publicado: (2022)

O-01: HYDROXYUREA REDUCES THE TRANSFUSION BURDEN IN CHILDREN WITH SICKLE CELL ANEMIA IN SUB-SAHARAN AFRICA: THE REACH EXPERIENCE
por: A., POWER-HAYS, et al.
Publicado: (2022)

Hydroxyurea Therapy for Children With Sickle Cell Anemia in Sub‐Saharan Africa: Rationale and Design of the REACH Trial
por: McGann, Patrick T., et al.
Publicado: (2015)

Parafoveal acute middle maculopathy (PAMM) in sickle cell disease after discontinuation of hydroxyurea
por: Parikh, Pooja, et al.
Publicado: (2022)

An integrated hospital-district evaluation for communicable diseases in low/middle-income countries
por: Tavoschi, L, et al.
Publicado: (2022)

Supporting Child Development Through Parenting Interventions in Low- to Middle-Income Countries: An Updated Systematic Review
por: Zhang, Linlin, et al.
Publicado: (2021)

P1474: MOLECURAL MECHANISM OF CHEMOTHERAPEUTIC HYDROXYUREA IS MEDIATED BY NOS2
por: Dragojević, T., et al.
Publicado: (2022)

SIGNIFICANT PREDICTORS OF INTEREST IN GERIATRICS AMONG LOW, MIDDLE, AND HIGH INCOME COUNTRIES
por: Karikari, Grace, et al.
Publicado: (2019)

Evidence-based interventions implemented in low-and middle-income countries for sickle cell disease management: A systematic review of randomized controlled trials
por: Gyamfi, Joyce, et al.
Publicado: (2021)

Food Consumption of People with Sickle Cell Anemia in a Middle-Income Country
por: Teixeira, Tamara Vilhena, et al.
Publicado: (2023)

Hydroxyurea and sickle cell anemia: effect on quality of life
por: Ballas, Samir K, et al.
Publicado: (2006)

Effective control of sickle cell disease with hydroxyurea therapy
por: Singh, Harminder, et al.
Publicado: (2010)

The influence of hydroxyurea on oxidative stress in sickle cell anemia
por: Torres, Lidiane de Souza, et al.
Publicado: (2012)

Evaluation of hydroxyurea genotoxicity in patients with sickle cell disease
por: de Oliveira, Emanuel Almeida Moreira, et al.
Publicado: (2019)

Inadequate WASH access and risk for non-partner sexual violence in low- and middle-income countries
por: Chi, H
Publicado: (2023)

ENHANCE—(Electronic Hydroxyurea Adherence): A Protocol to Increase Hydroxyurea Adherence in Patients with Sickle Cell Disease
por: Creary, Susan, et al.
Publicado: (2016)

Sickle Cell Disease and Infections in High- and Low-Income Countries
por: Cannas, Giovanna, et al.
Publicado: (2019)

1489. Safety and Performance of a Pharmacist-Driven Nasal MRSA PCR Protocol for De-escalation of Empiric Vancomycin for Suspected Pneumonia at an Academic Medical Center
por: Meng, Lina, et al.
Publicado: (2020)

Prevention, management, and rehabilitation of stroke in low- and middle-income countries
por: Yan, Lijing L., et al.
Publicado: (2016)

Management of neonatal jaundice in low- and lower-middle-income countries
por: Mir, Shahryar E, et al.
Publicado: (2019)

Recommendations for the Management of COVID-19 in Low- and Middle-Income Countries
por: Dondorp, Arjen M., et al.
Publicado: (2021)

Asthma management in low and middle income countries: case for change
por: Mortimer, Kevin, et al.
Publicado: (2022)

Models of lifelong care for children and adolescents with chronic conditions in low-income and middle-income countries: a scoping review
por: Reif, Lindsey K, et al.
Publicado: (2022)

Vaccine manufacturing capacity in low- and middle-income countries
por: Khan, Mohammed Imran, et al.
Publicado: (2021)

A systematic review on hydroxyurea therapy for sickle cell disease in India
por: Pandey, Apoorva, et al.
Publicado: (2022)

Dementia in low- and middle-income countries
por: Graham, Nori
Publicado: (2006)

P-075: HYDROXYUREA: EFFECTS ON TREATMENT OF CHILDREN WITH HEMOGLOBINOPATHY SC
por: A., CAMPOS, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_60r6k57cclneugrv0jnvr4o72d